Claims for Patent: 9,193,732

Summary for Patent: 9,193,732

Title:	Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo- [2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Abstract:	This invention relates to (1) process of making 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyr- imidine-6-carboxylic acid dimethylamide and salts thereof; (2) novel salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyr- imidine-6-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same.
Inventor(s):	Calienni; John Vincent (Cranford, NJ), Chen; Guang-Pei (Livingston, NJ), Gong; Baoqing (Morris Plains, NJ), Kapa; Prasad Koteswara (Parsippany, NJ), Saxena; Vishal (Quincy, MA)
Assignee:	Novartis AG (Basel, CH) Astex Therapeutics, LTD (Cambridge, GB)
Application Number:	13/882,353
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,193,732
Patent Claims:	1. Succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyr- imidine-6-carboxylic acid dimethylamide characterized by the initial X-ray Powder Diffraction (XRPD) illustrated in FIG. 2. 2. Succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyr- imidine-6-carboxylic acid dimethylamide characterized by the post-DVS X-ray Powder Diffraction (XRPD) illustrated in FIG. 2. 3. Succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyr- imidine-6-carboxylic acid dimethylamide characterized by the initial Differential Scanning Calorimetry (DSC) illustrated in FIG. 3. 4. Succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyr- imidine-6-carboxylic acid dimethylamide characterized by the post-DVS Differential Scanning Calorimetry (DSC) illustrated in FIG. 3. 5. Succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyr- imidine-6-carboxylic acid dimethylamide characterized by the initial Thermogravimetric Analysis (TGA) illustrated in FIG. 4. 6. Succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyr- imidine-6-carboxylic acid dimethylamide characterized by the post-DVS Thermogravimetric Analysis (TGA) illustrated in FIG. 4. 7. Succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyr- imidine-6-carboxylic acid dimethylamide characterized by the initial X-ray Powder Diffraction (XRPD) illustrated in FIG. 6. 8. Succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyr- imidine-6-carboxylic acid dimethylamide characterized by the post-DVS X-ray Powder Diffraction (XRPD) illustrated in FIG. 6. 9. A pharmaceutical composition comprising: (a) a therapeutically effective amount of a salt according to any of claims 1-8; and (b) at least one pharmaceutically acceptable carrier, diluent, vehicle or excipient.